Pure API’s from Nature & Reclaimed Sources

FeyeCon isolates and purifies active pharmaceutical ingredients from natural resources and industrial (waste) streams. Our processes are characterized by mild conditions, are cost-effective and produce high yields. In that way, we help you create pharmaceutical products that are innovative, pure and highly competitive on the market.

Stable Pharmaceutical Products with Improved Drug Availability

Affordable and smart medicines are our goal. FeyeCon develops processes for innovative solid drug particle formulations that open up more convenient administration routes, improving patient wellbeing and decreasing dosage. Our particle formation processes are compatible with every pharmaceutically accepted material.

Improved Shelf-life of Therapeutic Proteins & Peptides

FeyeCon improves shelf life and stability of proteins and peptides by making particle formulations loaded with fully preserved active ingredients. Particle sizes can vary from submicron to beads depending on processing conditions. The particles can be incorporated into medicines leading to higher concentrations of active ingredients and improved durability.  

Material Upgrading

FeyeCon's processes improve the quality and purity of materials used in medical devices. With our CO₂ technology we effectively remove contaminants, endotoxins, monomers, lipids, solvents and more. The process fully preserves the materials’ structure and even improves strength and appearance. The upgraded materials are not only of higher quality, but also safer and more convenient for patients.

Unique Medical Devices & Tissue Engineering Products

FeyeCon develops processes for high quality medical devices and tissue engineering materials with unique properties: increased material strength, safety and user convenience. FeyeCon helps you produce biodegradable porous implant materials like scaffolds, fibers, and foams. These can be impregnated with API’s – anti-infectives, growth factors – and can feature a triggered release ensuring a speedy and complication-free recovery.

Mild & Clean Sterilization

Sterilization using CO₂ is the mild and robust alternative for harsh chemical and radiation methods. The process ensures the highest possible level of sterilization without damaging any properties or leaving behind chemical residues. CO₂ sterilization inactivates a wide variety of toxins and can be integrated with other CO₂ assisted production steps. The shelf-life and quality of the medical products is significantly increased, leading to an improved positioning in the market.

		stdClass Object
(
    [vid] => 91
    [uid] => 1
    [title] => Pharmaceutical and Biomedical products 
    [log] => 
    [status] => 1
    [comment] => 2
    [promote] => 1
    [sticky] => 0
    [nid] => 91
    [type] => producten
    [language] => nl
    [created] => 1438594369
    [changed] => 1490022948
    [tnid] => 0
    [translate] => 0
    [revision_timestamp] => 1490022948
    [revision_uid] => 1
    [body] => Array
        (
            [nl] => Array
                (
                    [0] => Array
                        (
                            [value] => 

Pure API’s from Nature & Reclaimed Sources

FeyeCon isolates and purifies active pharmaceutical ingredients from natural resources and industrial (waste) streams. Our processes are characterized by mild conditions, are cost-effective and produce high yields. In that way, we help you create pharmaceutical products that are innovative, pure and highly competitive on the market.

Stable Pharmaceutical Products with Improved Drug Availability

Affordable and smart medicines are our goal. FeyeCon develops processes for innovative solid drug particle formulations that open up more convenient administration routes, improving patient wellbeing and decreasing dosage. Our particle formation processes are compatible with every pharmaceutically accepted material.

Improved Shelf-life of Therapeutic Proteins & Peptides

FeyeCon improves shelf life and stability of proteins and peptides by making particle formulations loaded with fully preserved active ingredients. Particle sizes can vary from submicron to beads depending on processing conditions. The particles can be incorporated into medicines leading to higher concentrations of active ingredients and improved durability.  

Material Upgrading

FeyeCon's processes improve the quality and purity of materials used in medical devices. With our CO₂ technology we effectively remove contaminants, endotoxins, monomers, lipids, solvents and more. The process fully preserves the materials’ structure and even improves strength and appearance. The upgraded materials are not only of higher quality, but also safer and more convenient for patients.

Unique Medical Devices & Tissue Engineering Products

FeyeCon develops processes for high quality medical devices and tissue engineering materials with unique properties: increased material strength, safety and user convenience. FeyeCon helps you produce biodegradable porous implant materials like scaffolds, fibers, and foams. These can be impregnated with API’s – anti-infectives, growth factors – and can feature a triggered release ensuring a speedy and complication-free recovery.

Mild & Clean Sterilization

Sterilization using CO₂ is the mild and robust alternative for harsh chemical and radiation methods. The process ensures the highest possible level of sterilization without damaging any properties or leaving behind chemical residues. CO₂ sterilization inactivates a wide variety of toxins and can be integrated with other CO₂ assisted production steps. The shelf-life and quality of the medical products is significantly increased, leading to an improved positioning in the market.

[summary] => [format] => full_html [safe_value] =>

Pure API’s from Nature & Reclaimed Sources

FeyeCon isolates and purifies active pharmaceutical ingredients from natural resources and industrial (waste) streams. Our processes are characterized by mild conditions, are cost-effective and produce high yields. In that way, we help you create pharmaceutical products that are innovative, pure and highly competitive on the market.

Stable Pharmaceutical Products with Improved Drug Availability

Affordable and smart medicines are our goal. FeyeCon develops processes for innovative solid drug particle formulations that open up more convenient administration routes, improving patient wellbeing and decreasing dosage. Our particle formation processes are compatible with every pharmaceutically accepted material.

Improved Shelf-life of Therapeutic Proteins & Peptides

FeyeCon improves shelf life and stability of proteins and peptides by making particle formulations loaded with fully preserved active ingredients. Particle sizes can vary from submicron to beads depending on processing conditions. The particles can be incorporated into medicines leading to higher concentrations of active ingredients and improved durability.  

Material Upgrading

FeyeCon's processes improve the quality and purity of materials used in medical devices. With our CO₂ technology we effectively remove contaminants, endotoxins, monomers, lipids, solvents and more. The process fully preserves the materials’ structure and even improves strength and appearance. The upgraded materials are not only of higher quality, but also safer and more convenient for patients.

Unique Medical Devices & Tissue Engineering Products

FeyeCon develops processes for high quality medical devices and tissue engineering materials with unique properties: increased material strength, safety and user convenience. FeyeCon helps you produce biodegradable porous implant materials like scaffolds, fibers, and foams. These can be impregnated with API’s – anti-infectives, growth factors – and can feature a triggered release ensuring a speedy and complication-free recovery.

Mild & Clean Sterilization

Sterilization using CO₂ is the mild and robust alternative for harsh chemical and radiation methods. The process ensures the highest possible level of sterilization without damaging any properties or leaving behind chemical residues. CO₂ sterilization inactivates a wide variety of toxins and can be integrated with other CO₂ assisted production steps. The shelf-life and quality of the medical products is significantly increased, leading to an improved positioning in the market.

[safe_summary] => ) ) ) [field_banner] => Array ( [und] => Array ( [0] => Array ( [fid] => 11 [uid] => 1 [filename] => recycling_waste.jpg [uri] => public://default_images/recycling_waste.jpg [filemime] => image/jpeg [filesize] => 342626 [status] => 1 [timestamp] => 1375988880 [rdf_mapping] => Array ( ) [is_default] => 1 [alt] => [title] => ) ) ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_white ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => big ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => black ) ) ) [field_liggende_image] => Array ( ) [field_staande_image] => Array ( ) [field_subtitel] => Array ( ) [field_video] => Array ( ) [field_gerelateerde_industrie_n] => Array ( [und] => Array ( [0] => Array ( [target_id] => 20 [entity] => stdClass Object ( [vid] => 20 [uid] => 1 [title] => Pharmaceutical and Biomedical [log] => [status] => 1 [comment] => 1 [promote] => 1 [sticky] => 0 [nid] => 20 [type] => industries [language] => nl [created] => 1376039461 [changed] => 1492505610 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1492505610 [revision_uid] => 1 [body] => Array ( [nl] => Array ( [0] => Array ( [value] =>

Healthy people and a Healthy planet

That is what FeyeCon aims for. Using CO₂ based processes for drug isolation, purification and formulation we create completely new and improved pharmaceutical and biomedical products. Our CO₂ technology is mild and leaves no residual solvents. It offers a very versatile and tunable process.  

Our mild and versatile CO₂ technology achieves:

  • High drug bioavailability
  • Increased product shelf-life
  • Improved patient wellbeing
  • Straightforward GMP upscaling

Our particles are characterized by:

  • High bioavailability
  • Tunable particle properties: size, morphology, density, crystal structures, polymorphisms
  • Tunable drug release properties
  • Full structural preservation of sensitive drugs
  • Different routes of administration

GMP Clean Room Facility 

At our laboratory in Weesp, The Netherlands, we have cGMP facilities that operate supercritical CO₂ equipment available to external parties. Our facilities - including a certified class D cleanroom - allow for the cGMP production of clinical batches and contract manufacturing.

Read more about our Pharmaceutical and Biomedical Technology

[summary] => [format] => full_html [safe_value] =>

Healthy people and a Healthy planet

That is what FeyeCon aims for. Using CO₂ based processes for drug isolation, purification and formulation we create completely new and improved pharmaceutical and biomedical products. Our CO₂ technology is mild and leaves no residual solvents. It offers a very versatile and tunable process.  

Our mild and versatile CO₂ technology achieves:

  • High drug bioavailability
  • Increased product shelf-life
  • Improved patient wellbeing
  • Straightforward GMP upscaling

Our particles are characterized by:

  • High bioavailability
  • Tunable particle properties: size, morphology, density, crystal structures, polymorphisms
  • Tunable drug release properties
  • Full structural preservation of sensitive drugs
  • Different routes of administration

GMP Clean Room Facility 

At our laboratory in Weesp, The Netherlands, we have cGMP facilities that operate supercritical CO₂ equipment available to external parties. Our facilities - including a certified class D cleanroom - allow for the cGMP production of clinical batches and contract manufacturing.

Read more about our Pharmaceutical and Biomedical Technology

[safe_summary] => ) ) ) [field_banner] => Array ( [und] => Array ( [0] => Array ( [fid] => 369 [uid] => 1 [filename] => shutterstock_105030071.jpg [uri] => public://banner/shutterstock_105030071.jpg [filemime] => image/jpeg [filesize] => 6251924 [status] => 1 [timestamp] => 1489152377 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 4928 [height] => 3264 ) ) ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_image ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => big ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => black ) ) ) [field_liggende_image] => Array ( ) [field_staande_image] => Array ( [und] => Array ( [0] => Array ( [fid] => 370 [uid] => 1 [filename] => shutterstock_105030071.jpg [uri] => public://content_staand/shutterstock_105030071.jpg [filemime] => image/jpeg [filesize] => 6251924 [status] => 1 [timestamp] => 1489152377 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 4928 [height] => 3264 ) ) ) [field_subtitel] => Array ( ) [field_video] => Array ( ) [field_icoon] => Array ( [und] => Array ( [0] => Array ( [fid] => 21 [uid] => 1 [filename] => icon_lifescience.png [uri] => public://industrieen/icon_lifescience.png [filemime] => image/png [filesize] => 313 [status] => 1 [timestamp] => 1376039461 [rdf_mapping] => Array ( ) [alt] => Life Science & Health care [title] => Life Science & Health care [width] => 31 [height] => 31 ) ) ) [field_gerelateerde_producten] => Array ( [und] => Array ( [0] => Array ( [target_id] => 32 ) [1] => Array ( [target_id] => 30 ) [2] => Array ( [target_id] => 28 ) [3] => Array ( [target_id] => 31 ) ) ) [field_gerelateerde_business_vent] => Array ( [und] => Array ( [0] => Array ( [target_id] => 41 ) [1] => Array ( [target_id] => 37 ) [2] => Array ( [target_id] => 52 ) [3] => Array ( [target_id] => 54 ) [4] => Array ( [target_id] => 39 ) [5] => Array ( [target_id] => 36 ) ) ) [field_sortering] => Array ( [und] => Array ( [0] => Array ( [value] => 4 ) ) ) [field_pagina_images] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1376039461 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} ) [access] => 1 ) ) ) [field_gerelateerde_business_vent] => Array ( [und] => Array ( [0] => Array ( [target_id] => 37 [entity] => stdClass Object ( [vid] => 37 [uid] => 1 [title] => Echo pharmaceuticals [log] => [status] => 1 [comment] => 1 [promote] => 1 [sticky] => 0 [nid] => 37 [type] => business [language] => nl [created] => 1376382057 [changed] => 1383131788 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1383131788 [revision_uid] => 1 [body] => Array ( [nl] => Array ( [0] => Array ( [value] =>

Echo pharmaceuticals

Echo Pharmaceuticals is focused on the formulation, production and development of pharmaceutical products based on cannabis components. Cannabis-based medicines have a long history and are proven to be effective for the treatment of pain, nausea, spasticity and various other symptoms. Their first product Namisol®, a tablet targeted to relieve the symptoms of multiple sclerosis and neurological pain, has recently passed clinical trial phase 2. 

 

[summary] => [format] => full_html [safe_value] =>

Echo pharmaceuticals

Echo Pharmaceuticals is focused on the formulation, production and development of pharmaceutical products based on cannabis components. Cannabis-based medicines have a long history and are proven to be effective for the treatment of pain, nausea, spasticity and various other symptoms. Their first product Namisol®, a tablet targeted to relieve the symptoms of multiple sclerosis and neurological pain, has recently passed clinical trial phase 2. 

 

[safe_summary] => ) ) ) [field_banner] => Array ( ) [field_liggende_image] => Array ( [und] => Array ( [0] => Array ( [fid] => 46 [uid] => 1 [filename] => Logo_echo.png [uri] => public://content_liggend/Logo_echo.png [filemime] => image/png [filesize] => 11719 [status] => 1 [timestamp] => 1376382057 [rdf_mapping] => Array ( ) [alt] => echo_pharmaceuticals [title] => echo_pharmaceuticals [width] => 220 [height] => 140 ) ) ) [field_staande_image] => Array ( ) [field_subtitel] => Array ( ) [field_video] => Array ( ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_image ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => small ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => black ) ) ) [field_gerelateerde_industrie_n] => Array ( [und] => Array ( [0] => Array ( [target_id] => 20 ) ) ) [field_gerelateerde_producten] => Array ( [und] => Array ( [0] => Array ( [target_id] => 31 ) ) ) [field_url] => Array ( [und] => Array ( [0] => Array ( [value] => http://www.echo-pharma.com [format] => [safe_value] => http://www.echo-pharma.com ) ) ) [field_pagina_images] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1376382057 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} ) [access] => 1 ) [1] => Array ( [target_id] => 52 [entity] => stdClass Object ( [vid] => 52 [uid] => 1 [title] => InProPharma [log] => [status] => 1 [comment] => 1 [promote] => 1 [sticky] => 0 [nid] => 52 [type] => business [language] => nl [created] => 1376397637 [changed] => 1383131744 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1383131744 [revision_uid] => 1 [body] => Array ( [nl] => Array ( [0] => Array ( [value] =>

InProPharma

InProPharma is a biotechnology research and development company specialized in services for development of generic products, bio-similars, bio-betters, New Molecular Entities (NME’s) and New Chemical Entities (NCE’s). InProPharma works for clients in the biotechnology and pharmaceutical industry. Their services include the performance of lead optimization, preclinical research and regulatory, pharmacokinetic studies. Support in toxicology studies, safety studies, human safety trials, coordination of clinical trials and support to obtain marketing authorization is also offered.

 

[summary] => [format] => full_html [safe_value] =>

InProPharma

InProPharma is a biotechnology research and development company specialized in services for development of generic products, bio-similars, bio-betters, New Molecular Entities (NME’s) and New Chemical Entities (NCE’s). InProPharma works for clients in the biotechnology and pharmaceutical industry. Their services include the performance of lead optimization, preclinical research and regulatory, pharmacokinetic studies. Support in toxicology studies, safety studies, human safety trials, coordination of clinical trials and support to obtain marketing authorization is also offered.

 

[safe_summary] => ) ) ) [field_banner] => Array ( ) [field_liggende_image] => Array ( [und] => Array ( [0] => Array ( [fid] => 87 [uid] => 1 [filename] => Logo_Inpropharma.png [uri] => public://content_liggend/Logo_Inpropharma.png [filemime] => image/png [filesize] => 3057 [status] => 1 [timestamp] => 1376397637 [rdf_mapping] => Array ( ) [alt] => inpropharma [title] => inpropharma [width] => 220 [height] => 140 ) ) ) [field_staande_image] => Array ( ) [field_subtitel] => Array ( ) [field_video] => Array ( ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_image ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => small ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => black ) ) ) [field_gerelateerde_industrie_n] => Array ( [und] => Array ( [0] => Array ( [target_id] => 20 ) ) ) [field_gerelateerde_producten] => Array ( ) [field_url] => Array ( [und] => Array ( [0] => Array ( [value] => http://www.inpropharma.com [format] => [safe_value] => http://www.inpropharma.com ) ) ) [field_pagina_images] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1376397637 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} ) [access] => 1 ) [2] => Array ( [target_id] => 39 [entity] => stdClass Object ( [vid] => 39 [uid] => 1 [title] => TERSUS Solutions [log] => [status] => 1 [comment] => 1 [promote] => 1 [sticky] => 0 [nid] => 39 [type] => business [language] => nl [created] => 1376382136 [changed] => 1426078096 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1426078096 [revision_uid] => 1 [body] => Array ( [nl] => Array ( [0] => Array ( [value] =>

TERSUS Solutions

The TERSUS Solution redefines textile processing by replacing water with recycled carbon dioxide. Our process enables the efficient production and maintenance of higher performing, longer lasting textiles and garments. The TERSUS platform uses less energy and nearly eliminates water from textile cleaning, treatment, and finishing processes. TERSUS, by CO2Nexus, currently works with brand apparel companies and cleanroom garment service companies where we enable them to produce and maintain more environmentally-responsible textiles and garments." 

TERSUS – redefining textile processing

[summary] => [format] => full_html [safe_value] =>

TERSUS Solutions

The TERSUS Solution redefines textile processing by replacing water with recycled carbon dioxide. Our process enables the efficient production and maintenance of higher performing, longer lasting textiles and garments. The TERSUS platform uses less energy and nearly eliminates water from textile cleaning, treatment, and finishing processes. TERSUS, by CO2Nexus, currently works with brand apparel companies and cleanroom garment service companies where we enable them to produce and maintain more environmentally-responsible textiles and garments." 

TERSUS – redefining textile processing

[safe_summary] => ) ) ) [field_banner] => Array ( ) [field_liggende_image] => Array ( [und] => Array ( [0] => Array ( [fid] => 223 [uid] => 1 [filename] => Tersus small.PNG [uri] => public://content_liggend/Tersus small.PNG [filemime] => image/png [filesize] => 36642 [status] => 1 [timestamp] => 1413192449 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 335 [height] => 261 ) ) ) [field_staande_image] => Array ( ) [field_subtitel] => Array ( [und] => Array ( [0] => Array ( [value] => by CO2Nexus, Inc. [format] => [safe_value] => by CO2Nexus, Inc. ) ) ) [field_video] => Array ( [und] => Array ( [0] => Array ( [video_url] => http://youtu.be/9qqOcXgCjyY [thumbnail_path] => public://video_embed_field_thumbnails/youtube/9qqOcXgCjyY .jpg [video_data] => a:1:{s:7:"handler";s:7:"youtube";} [embed_code] => [description] => Patagonia invest in CO2Nexus ) ) ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_image ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => small ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => black ) ) ) [field_gerelateerde_industrie_n] => Array ( [und] => Array ( [0] => Array ( [target_id] => 14 ) ) ) [field_gerelateerde_producten] => Array ( [und] => Array ( [0] => Array ( [target_id] => 33 ) ) ) [field_url] => Array ( [und] => Array ( [0] => Array ( [value] => http://tersussolutions.com/ [format] => [safe_value] => http://tersussolutions.com/ ) ) ) [field_pagina_images] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1376382136 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} ) [access] => 1 ) [3] => Array ( [target_id] => 36 [entity] => stdClass Object ( [vid] => 36 [uid] => 1 [title] => Tispa medical [log] => [status] => 1 [comment] => 1 [promote] => 1 [sticky] => 0 [nid] => 36 [type] => business [language] => nl [created] => 1376381993 [changed] => 1383132165 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1383132165 [revision_uid] => 1 [body] => Array ( [nl] => Array ( [0] => Array ( [value] =>

Tispa Medical

Tispa Medical’s mission is to introduce true solvent free histological tissue processing equipment, to offer laboratories, their staff and the environment a healthier and sustainable alternative as well as faster and better histological results. The Tispa Medical Processor is the first ever tissue processing machine based on supercritical CO₂ . The process uses no solvents, processes significantly more samples per batch and processes so quickly that same day diagnosis is possible.

 

[summary] => [format] => full_html [safe_value] =>

Tispa Medical

Tispa Medical’s mission is to introduce true solvent free histological tissue processing equipment, to offer laboratories, their staff and the environment a healthier and sustainable alternative as well as faster and better histological results. The Tispa Medical Processor is the first ever tissue processing machine based on supercritical CO₂ . The process uses no solvents, processes significantly more samples per batch and processes so quickly that same day diagnosis is possible.

 

[safe_summary] => ) ) ) [field_banner] => Array ( ) [field_liggende_image] => Array ( [und] => Array ( [0] => Array ( [fid] => 45 [uid] => 1 [filename] => Logo_tispa.png [uri] => public://content_liggend/Logo_tispa.png [filemime] => image/png [filesize] => 5698 [status] => 1 [timestamp] => 1376381993 [rdf_mapping] => Array ( ) [alt] => Tispa_medical [title] => Tispa_medical [width] => 220 [height] => 140 ) ) ) [field_staande_image] => Array ( ) [field_subtitel] => Array ( ) [field_video] => Array ( ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_image ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => small ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => black ) ) ) [field_gerelateerde_industrie_n] => Array ( [und] => Array ( [0] => Array ( [target_id] => 20 ) ) ) [field_gerelateerde_producten] => Array ( [und] => Array ( [0] => Array ( [target_id] => 33 ) ) ) [field_url] => Array ( [und] => Array ( [0] => Array ( [value] => http://www.tispamedical.com [format] => [safe_value] => http://www.tispamedical.com ) ) ) [field_pagina_images] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1376381993 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} ) [access] => 1 ) ) ) [field_pagina_images] => Array ( [und] => Array ( [0] => Array ( [fid] => 257 [uid] => 1 [filename] => shutterstock_177013178 (800x533).jpg [uri] => public://shutterstock_177013178 (800x533).jpg [filemime] => image/jpeg [filesize] => 183737 [status] => 1 [timestamp] => 1438596828 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 800 [height] => 533 ) ) ) [field_url] => Array ( ) [field_brochure] => Array ( ) [field_attachment] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1438594369 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} [entity_view_prepared] => 1 )